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OBJECTIVE—The aim of this study was to evaluate the efﬁ-
ciency and safety of simultaneous islet and kidney transplanta-
tion in patients with type 1 diabetes and end-stage renal disease
using a glucocorticoid-free immunosuppressive regimen with
alemtuzumab induction.
RESEARCH DESIGN AND METHODS—Seven patients with
type 1 diabetes and end-stage renal failure were transplanted
with allogenic islets and kidneys procured from brain-dead
donors. To prevent organ rejection, patients received alemtu-
zumab for induction immunosuppression, followed by sirolimus
and tacrolimus. No glucocorticoids were given at any time.
RESULTS—The median duration of follow-up was 18.3 months
(range 13–31). Kidney survival was 100%. Four patients became
insulin independent at 1 year. The other three reduced insulin
use to less than 25% of the amount required before transplanta-
tion. Serum C-peptide levels were signiﬁcantly greater posttrans-
plant in all patients, indicating continued islet function. No major
procedure-related complications were observed.
CONCLUSIONS—Our results demonstrate that a steroid-free
immunosuppressive regimen consisting of alemtuzumab, siroli-
mus, and tacrolimus is feasible for simultaneous islet and kidney
transplantation. The question of whether this induction regimen
is superior to more standard induction deserves large studies.
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T
ype 1 diabetes remains a therapeutic challenge.
Although intensive diabetes treatment reduces
incidence and delays progression of long-term
complications, including retinopathy, nephropa-
thy, and neuropathy, the beneﬁts of intensive diabetes
treatment come with the price of severe hypoglycemia and
increased body weight (1). Islet transplantation represents
a most impressive recent advance in the search for better
type 1 diabetes treatment, with an encouraging rate of
insulin independence, normalization of blood glucose, and
lowered A1C levels and improved quality of life after either
pancreas or islet transplantation (2–7).
Type 1 diabetes can itself impair kidney function. It is
therefore generally accepted to perform combined pancre-
as/kidney transplantation rather than kidney transplanta-
tion alone for patients with brittle diabetes and end-stage
kidney disease because pancreas transplantation can im-
prove kidney graft survival (8). Unfortunately, the positive
impact of pancreas transplantation on the native kidney
has been counterbalanced by the toxicity that steroids and
calcineurin inhibitors pose to islet cells and the serious
complications of pancreas transplantation.
In 2000, using a glucocorticoid-free immunosuppressive
protocol that included sirolimus, low-dose tacrolimus, and
a monoclonal antibody against the interleukin-2 receptor
(IL-2R) (daclizumab), Shapiro et al. (9) carried out islet
transplantation alone for seven patients with type 1 diabe-
tes and a history of severe hypoglycemia and metabolic
instability. They demonstrated that islet transplantation
can result in insulin independence with excellent meta-
bolic control when glucocorticoid-free immunosuppres-
sion is combined with the infusion of an adequate islet
mass. This treatment became known as the Edmonton
Protocol. As of 1 November 2004, 65 patients have re-
ceived islet transplants at the University of Alberta, and
results have been promising: the majority (80%) of the
recipients have had C-peptide present following islet trans-
plant. Unfortunately, the median duration of insulin inde-
pendence has been 15 months, and only a minority (10%)
have maintained insulin independence 5 years following
islet transplant (10).
Alemtuzumab (Campath-1H) is a 150-kDa humanized
IgG1 monoclonal antibody that targets the CD52 antigen, a
glycoprotein found on the cell surface of many cell types,
including lymphocytes and monocytes. Alemtuzumab is
currently approved for the treatment of -cell chronic
lymphocytic leukemia in patients who have been previ-
ously treated with an alkylating agent and who have failed
to beneﬁt from ﬂudarabine therapy (11). Alemtuzumab has
been used off label in solid-organ transplantation exten-
sively, especially as an induction agent (12). Prolonged
lymphocyte depletion can be expected following alemtu-
zumab treatment with 30 mg intravenous dose. The
majority of alemtuzumab use experience in solid-organ
transplantation has been in kidney transplantation; there
is more limited experience in islet transplantation. In an
observational cohort study, 75 pancreas/kidney and pan-
creas-only recipients received alemtuzumab and mycophe-
nolate mofetil for induction and maintenance therapy;
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alemtuzumab and mycophenolate mofetil was associated
with an acceptable rejection rate, a good safety proﬁle,
and a trend toward higher modiﬁcation of renal disease
levels. Kaufman et al. (14) reported that alemtuzumab
induction followed by steroid-free maintenance therapy
with a tacrolimus/sirolimus-based immunosuppression
regimen is effective and safe in simultaneous pancreas/
kidney transplantation compared with rabbit antithymo-
cyte globulin induction. Here we report the 13- to 31-
month follow-up of seven patients with type 1 diabetes and
end-stage diabetic nephropathy receiving simultaneous
islet and kidney transplantation in which alemtuzumab
was used for induction immunosuppression.
RESEARCH DESIGN AND METHODS
This was a single-center pilot trial conducted from June 2005 to December
2006. A total of seven patients (four women and three men) with end-stage
renal disease and type 1 diabetes with serum C-peptide level 0.3 ng/ml
were enrolled. The main inclusion criterion was severe hypoglycemia
(blood glucose level 50 mg/dl) during the past 3 years that required
infusion of glucose. The mean age of the patients was 39.7 years (range
32–46) and duration of diabetes 14.8 years (9–25). Patients had undergone
hemodialysis dialysis treatment for 10 months (3–24). Detailed recipient
characteristics are shown in Table 1. The speciﬁcity of the anti-HLA
antibodies was determined by ELISA (Lambda Antigen Tray, LAT 1240, lot
6#; One Lambda, Canoga Park, CA). The study protocol was approved by
the ethics review committee of our hospital, and written informed consent
was obtained from all participants.
Islet preparation. Islets were isolated from pancreata obtained from
cadaveric multiorgan donors using a modiﬁed method described previously
(15). Brieﬂy, human cadaveric pancreata were removed from brain-dead
donors after they had been pronounced brain dead in our hospital. The
causes of death of the organ donors were trafﬁc accidents. Cold-ischemia
time of the 16 pancreata averaged 5.7 h (range 2–10.4). The pancreatic duct
was perfused with a cold enzyme (Liberase human islet; Roche Diagnos-
tics, Indianapolis, IN). The pancreas was enzymatically and mechanically
dissociated before the islets were separated on a refrigerated Cobe 2991
centrifuge (Cobe BCT, Lakewood, CO). Puriﬁcation was performed by
centrifugation on continuous Ficoll gradients (Seromed-Biochrom). Islets
were cultured in CMRL1066 medium (Mediatech-Cellgro) supplemented
with 0.5% human serum albumin and incubated at 37°C in 5% CO2 and 95%
humidiﬁed air for 12–24 h. Islet numbers were quantiﬁed in duplicate with
the use of an islet standard diameter of 150 m and tested for sterility,
endotoxin, and mycoplasma.
Transplantation procedures. The protocol was approved by the ethics
review committee of our hospital. Kidney transplantation was performed in a
routine procedure of our hospital, which has carried out more than 3,000
cases of kidney transplantation. Islets were infused in the liver as previously
described (9), with modiﬁcations. Brieﬂy, under local anesthesia (a mixture of
50% lidocaine [2%] and 50% ropivacaine [1%]), a 5-cm incision was made in the
upper abdomen to expose the umbilical vein, which was usually 4 cm above
the navel. A small incision was made in the umbilical vein. Then, a 7F biliary
bougie was inserted. The tip of the bougie was directed toward the liver. The
bougie was replaced by a 16F catheter when it reached the sagittal sinus. After
the position of the catheter was conﬁrmed to be correct by portography, the
islets in 250 ml medium in an intravenous ﬂuid bag were allowed to infuse for
30 min. Portal pressure was monitored during and after infusion, which was in
the range of 7–11 mm H2O. The catheter was then secured to the skin so that
multiple deliveries of islets could be achieved later.
Immunosuppression. All patients were treated according to the Edmonton
Protocol (9), with some modiﬁcations. Brieﬂy, the protocol includes 1)
alemtuzumab (induction immunosuppression), administered by intravenous
infusion at a dose of 15 mg 24 h before transplantation and repeated 24 h after
islet infusion, with patient’s peripheral blood lymphocyte count 50 cells/ml;
2) sirolimus at 0.2 mg/kg for the ﬁrst 10 days with target plasma levels of 12–15
ng/ml followed by a maintenance dose of 0.1 mg/kg once daily, with target
plasma levels of 10–12 ng/ml for the next 30 days; and, following dose
adjustment to achieve target plasma levels of 7 ng/ml, 3) tacrolimus at 2–3
mg/day adjusted to achieve a target plasma level of 3–5 ng/ml. No glucocor-
ticoids were given at any time during the trial.
Other medications. Short-term antibiotic prophylaxis was administered
immediately before and after islet infusion (intravenous ceftazidime, 1 g t.i.d.
for 1 day). For 3 months after islet infusion, patients were treated with
trimethoprim (800 mg/day), sulfamethoxazole (1,000 mg, twice a week), and
Valcye (450 mg b.i.d.) to prevent Pneumocystis carinii and cytomegalo-
virus infection. During the ﬁrst 3 days after islet infusion, insulin was
administered intravenously using an infusion pump and then subcutane-
ously until withdrawal.
Postprocedural monitoring and management. Glucose was monitored
every 2–4 h in the ﬁrst 2 days posttransplant. After a normal diet was resumed,
the patients were monitored for glucose levels preprandially, 2 h postprandi-
ally, and before sleep. Fasting and postprandial C-peptide levels, blood tests
and liver and kidney functions were evaluated weekly. Glycated hemoglobin
and anti-insulin antibody were checked monthly. Serum concentrations of
immunosuppressants were checked weekly after transplantation and 1–2
times monthly when they reached the targeted concentrations. Sera of all
subjects were monitored for islet cell antibodies, anti-insulin autoantibodies,
and GAD glutamic acid decarboxylase antibodies using the ELISA technique.
Cutoff values of 1.00, 1.00–1.050, and 1.050 units/m were considered
negative, indeterminate, or positive, respectively.
Therapeutic efﬁcacy. The primary end points were the proportion of
recipients who achieve insulin independence in the ﬁrst year, kidney graft
loss, doubling of serum creatinine, or death. We deﬁned recipients as insulin
independent if they maintained fasting blood glucose levels 126 mg/dl (7.0
mmol/l) and 2-h postprandial levels 180 mg/dl (10.0 mmol/l) after discontin-
uation of insulin.
Statistical analysis. Statistical analysis was performed using SPSS for
Windows (version 10.1; SPSS, Chicago, IL). Data are presented as means 
SD. Data were analyzed using one-way ANOVA. If the F ratios were signiﬁcant,
post hoc tests were applied to assess signiﬁcance (P  0.05).
TABLE 1
Recipient characteristics for each of seven pretransplant islet recipients
Recipient
1234567
Age (years) 34 44 43 40 32 46 39
Sex F F F M M M F
Body weight (kg) 45 54 46 55 70 68 51
BMI (kg/m
2) 18.8 21.1 19.7 21.0 23.7 22.0 20.4
Diabetes duration (years) 13 15 25 14 15 9 13
Daily insulin (IU/day) 54 64 36 52 60 48 54
A1C (%) 8.0 7.8 8.8 9.5 8.9 10.0 9.5
Baseline glucose level (mmol/l) 7.8 8.0 8.5 8.7 8.0 8.9 8.5
Hemodialysis (months) 6 3 19 4 8 24 6
Serum creatinine (mol/l) 453 427 460 403 615 558 424
Panel reactive antibodies (%) 0 0 2.5 0 2.5 0 2.5
HLA mismatch* (A, B, DR) 3323233
*HLA mismatch between the recipient and the kidney donor, who was also the donor of the ﬁrst islet in case of multiple islet transplantation.
F, female; M, male.
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Characteristics of the patients. Seven consecutive pa-
tients (median age 39.7 years [range 32–46]) who had type
1 diabetes for a median of 14.8 years (9–25) and end-stage
renal disease underwent combined islet and kidney trans-
plantation between June 2005 and December 2006. As of
January 2008, the median duration of follow-up was 18.3
months (13–31). Detailed recipient and donor characteris-
tics are shown in Tables 1 and 2.
Transplantation. The number of islets harvested was
450,000–760,000 islet equivalents (IEQs). Islet purity and
viability were 94.3% (range 92–96) and 91.6% (91–93),
respectively. The stimulation index, deﬁned as the ratio of
secreted insulin from the high-glucose to the low-glucose
incubation, was 2.33 (2.1–3.05). No viruses or bacteria
were detected in either islet preparation.
Therapeutic efﬁcacy. The number of islets infused was
11,820 IEQ/kg (range 10,000–15,556 IEQ/kg of the recipi-
ent’s body weight). Three of the seven patients received
only one islet transplantation (patients 3, 6, and 7). Patient
3 become insulin independent at 34 days posttransplanta-
tion and remained free of the need for exogenous insulin
thereafter. Patients 6 and 7 did not receive a second islet
infusion because of islet shortage, and they did not be-
come insulin independent, but both of them decreased
their insulin dose by more than 60%. Three patients
(patients 2, 4, and 5) required a second islet infusion from
a second donor pancreas a median of 45 days (30–90) after
the ﬁrst procedure. Patients 2 and 4 became insulin
independent thereafter, but patient 5 required 8 IU insulin
per day. Patient 1 required three islet infusions to achieve
insulin independence. Thus, four (57.1%) of the patients
became insulin independent, and insulin requirements
decreased in all patients after the ﬁrst transplantation
(Table 3). All patients attained near-normal A1C values
after transplantation (Table 4 and Fig. 1).
Serum C-peptide concentrations were 0.1–0.25 ng/ml
before transplantation. During the follow-up period, per-
sistent C-peptide secretion was evident. One month after
transplantation, all patients had serum C-peptide concen-
trations above 0.5 ng/ml, and the concentrations did not
decrease over time: at three months, the mean fasting
TABLE 2
Donor characteristics
Patient and
infusion
procedure no.
Age
(years)
BMI
(kg/m
2)
Duration of cold
ischemia
(hours)
Weight of
pancreas (g)
Islet
yield (IEQ)
Islet
viability
(%)
Stimulus
index
Cross-match
(%)
Patient 1
1 33 24 5 95.8 460,733 94 2.47 2
2* 34 21.4 2 84 387,000 95 2.15 3
2* 42 22.0 7 92 240,000 93 2.23 2
3 36 23.5 3.75 100.4 628,200 95 3.05 3
Patient 2
1 38 23.4 8.3 95.6 587,467 95 2.48 3
2* 31 23.7 5 90.8 226,650 95 2.37 3
2* 37 22.0 9.5 93 429,200 95 2.18 2
Patient 3
1 43 24 6 95 495,600 95 2.27 3
Patient 4
1* 32 23.7 5 130.8 314,958 92 2.12 2
1* 36 20.4 10.4 93.1 385,567 95 2.58 3
2* 28 21.8 4.5 97 325,044 94 2.24 2
2* 34 24 8 113.7 382,733 93 2.10 2
Patient 5
1 39 24.3 7 94 587,950 92 2.32 3
2 43 24.5 2 133.7 669,400 95 2.27 3
Patient 6 35 23 3.5 123.2 760,517 95 2.55 3
Patient 7 35 23.3 4.25 94.2 559,267 96 2.17 3
*Islets from two donors were infused in the same procedure for each patient.
TABLE 3
Procedural characteristics after the last transplantation
Subject
Baseline insulin
requirement
(IU/day)
Total
transplantations
Insulin requirement after the last transplantation (IU/day)
Insulin independent
time (months) 1 month 2 months 3 months 6 months 12 months
1 5 4 3 1 2000 0 2 0
2 64 2 16 10 0 0 0 21
3 3 6 1 1 0000 0 1 9
4 52 2 16 12 8 8 0 10
5 60 2 28 18 12 12 8 13%*
6 48 1 16 20 20 16 12 25%*†
7 54 1 24 26 26 18 14 26%*†
*Insulin use after the last transplantation as a percentage of the amount required before transplantation. †Patients 6 and 7 had only one islet
infusion each because of nonavailability of additional islets.
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meal was 1.65  0.37 ng/ml; at six months, the mean
fasting value was 1.30  0.56 ng/ml and the mean value
after a meal was 1.71  0.44 ng/ml; at twelve months, the
mean fasting value was 1.42  0.49 ng/ml and the mean
value after a meal was 2.33  0.57 ng/ml. Thus, all patients
were C-peptide positive (0.5 ng/ml) during the ﬁrst year
posttransplant (Table 4 and Fig. 1).
Sera of all subjects were monitored for islet cell anti-
bodies, anti-insulin autoantibodies, and GAD antibodies
using the ELISA technique. According to the considered
cutoff point for positivity, none of the patients tested
positive for these antibodies. All patients had repeated
episodes of severe hypoglycemia before transplantation
but have had no further episodes since transplantation.
This change has dramatically improved their quality of life.
Renal and liver function. Kidney function became nor-
mal 5 days after transplantation (with a serum concentra-
tion of creatinine 100 mol/l) and remained normal
thereafter (Fig. 1). The time course of glomerular ﬁltration
rate largely mirrored that of serum creatinine concentra-
tion. Glomerular ﬁltration rate signiﬁcantly increased to
near normal posttransplant (56–85.6 ml/min; Fig. 2).
Doppler ultrasonography demonstrated no evidence of
thrombus within the portal vein in any of the patients. The
patients were hospitalized for a median of 21 days (range
15–28). No acute graft rejection or graft loss occurred
during the 1 year of follow-up. The results of tests of liver
function 24 h before and after transplantation were within
the normal range for all patients and remained normal
thereafter.
Other biochemical parameters. None of the patients
had overt proteinuria at baseline or developed proteinuria
thereafter. In all study groups, there was no signiﬁcant
change in serum cholesterol level compared with baseline
values. Mean values of serum sodium and potassium
concentrations (data not shown) were comparable before
and at the end of the study period in all groups.
Safety. The packed cell volume ranged from 0.8 to 2.5 ml.
The infused volume was 250 ml for each islet prepara-
tion, and this did not change the portal pressure signiﬁ-
cantly (mean increase 1–2 cm H2O). The portal vein
pressure ranged from 7 to 11 cm H2O after islet infusion.
Mouth ulcerations were observed in two patients and
cystitis in two patients. None of the patients had cytomeg-
alovirus infection or sirolimus-related cytopenia. There
have been no episodes of acute rejection of kidney or
islets as determined by measurements of creatinine, gly-
cemic control, serum insulin, and C-peptide. None of the
patients have died.
DISCUSSION
In this report, we describe—for the ﬁrst time—the results
of simultaneous islet and kidney transplant in patients
who have received a glucocorticoid-free immunosuppres-
sive protocol that consisted of sirolimus, low-dose tacroli-
mus, and a monoclonal antibody against CD52 antigen
(alemtuzumab). For patients with brittle diabetes and
end-stage renal disease, survival is extremely poor, and
kidney transplantation does not completely improve the
situation (16–18). Sequential kidney and islet transplanta-
tion has been carried out with good results. In this
situation, steroids were withdrawn in kidney recipients
before islets were transplanted. The foremost challenge in
simultaneous transplantation of islet and kidney is to
TABLE 4
A1C and C-peptide levels after islet transplantation
A1C
C-peptide
before meal
(ng/ml)
C-peptide
after meal
(ng/ml)
Pretransplantation 8.93  0.81 0.06  0.08 0.11  0.09
1 month posttransplantation 6.59  0.64* 0.84  0.25* 1.18  0.31*
3 months posttransplantation 5.96  0.42* 1.00  0.29* 1.65  0.37*
6 months posttransplantation 6.14  0.72* 1.30  0.56* 1.71  0.44*
12 months posttransplantation 6.31  0.82* 1.42  0.49* 2.33  0.57*
Last examination 6.31  0.82* 1.33  0.39* 2.50  0.71*
Data are means  SD. *P  0.01 compared with pretransplantation.
0
2
4
6
8
10
12
A B C
036 1 2 1 8
H
b
A
1
c
(
%
)
month month month
Pt1
Pt2
Pt3
Pt4
Pt5
Pt6
Pt7
0
0.5
1
1.5
2
2.5
0 1 3 6 12 18
C
-
p
e
p
t
i
d
e
 
b
e
f
o
r
e
 
m
e
a
l
 
(
n
g
/
m
l
)
Pt1
Pt2
Pt3
Pt4
Pt5
Pt6
Pt7
0
0.5
1
1.5
2
2.5
3
3.5
4
0 1 3 6 12 18
C
-
p
e
p
t
i
d
e
 
a
f
t
e
r
 
m
e
a
l
 
(
n
g
/
m
l
)
Pt1
Pt2
Pt3
Pt4
Pt5
Pt6
Pt7
FIG. 1. Metabolic control and islet graft function after transplantation. Values of A1C data (A) show improvement in all patients after islet
transplantation. Results of premeal (B) and postmeal (C) C-peptide values demonstrate the beneﬁts of the transplant on metabolic control
during the follow-up period.
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against -cells without the use of steroids in the immuno-
suppression regimen because steroids are considered fa-
vorable for prevention of organ rejection but harmful for
islets (19,20). Recently, monoclonal antibodies directed
against speciﬁc T-cell surface molecules have been devel-
oped for clinical use as immunosuppressants. One of these
is anti-CD25 (daclizumab), a humanized IgG1 monoclonal
antibody directed against the low-afﬁnity IL-2R -chain
(21). This antibody is supposed to solely affect activated
T-cells. It has been used in simultaneous kidney and
pancreas/islet transplantation with or without steroids
(22,23). Although glucocorticoid-free immunosuppression
containing daclizumab has greatly contributed to the suc-
cess of islet transplantation, in the case of simultaneous
islet and kidney transplantation it is still a great risk to use
a glucocorticoid-free immunosuppression regimen. The
recipients may run the genuine risk of jeopardizing the
function of their kidney grafts at the time of switching
immunosuppression and/or the weaning of steroids. This
happened, unfortunately, in the pilot study reported by
Toso et al. (24), in which one patient lost his kidney graft
several months after islet-after-kidney transplantation. In
fact, even in kidney transplant recipients receiving an
immunosuppression regimen containing daclizumab, cy-
closporine, azathioprine, and prednisone, the proportion
of recipients who had biopsy-conﬁrmed episodes of acute
rejection still reached 22% (25).
Alemtuzumab (Campath-1H), a 150-kDa humanized
IgG1 monoclonal antibody that targets the CD52 antigen,
has been used extensively in solid-organ transplanta-
tion, especially in kidney transplantation, with the aim
of allowing steroid-free and/or calcineurin-free or spar-
ing maintenance immunosuppressive protocols (12,26,27).
Alemtuzumab is an attractive agent for induction. It pro-
duces profound and long-lasting lymphopenia. In an at-
tempt to reduce both initial and long-term (nephrotoxic)
calcineurin inhibitor maintenance dosage and totally elim-
inate maintenance corticosteroids, Ciancio et al. used
alemtuzumab as induction therapy ﬁrst in cadaver and
then in non–HLA-identical living-donor renal transplanta-
tion. No corticosteroids were given after the ﬁrst week
posttransplant. In 44 de novo renal allograft recipients,
patient and graft survival rates were each at 100% during a
median follow-up of 9 months (27). Biopsy-proven acute
rejection was diagnosed in four patients. Their results
demonstrated that the combination of alemtuzumab, low
doses of tacrolimus and mycophenolate mofetil, and
avoidance of maintenance corticosteroid is safe and effec-
tive for kidney transplant recipients. Several other studies
also demonstrated that when alemtuzumab was used for
induction immunosuppression for kidney recipients, pa-
tients might be maintained on steroid-free immunosup-
pressive regimens (28–29). Simultaneous pancreas/kidney
transplantation using alemtuzumab as a means of induc-
tion immunosuppression has also been performed (30,14).
In the study by Kaufman et al. (14), alemtuzumab induc-
tion followed by steroid-free maintenance therapy with a
tacrolimus- and sirolimus-based immunosuppression regi-
men was shown to be effective and safe. In the study by
Gruessner et al. (13), only alemtuzumab and mycopheno-
late mofetil were included in the immunosuppression
regimen, which resulted in a higher, but still acceptable,
incidence of a ﬁrst reversible rejection episode for simul-
taneous pancreas/kidney recipients compared with soli-
tary pancreas recipients. Although the question of whether
alemtuzumab is more effective than thymoglobulin or
antiIL-2R receptor antibodies cannot be answered at this
time, it appears that the incidence of acute rejection is low
after induction with alemtuzumab, and there is no appar-
ent increase in infection (26).
Based on these observations, we chose a steroid-free
regimen that contained alemtuzumab, sirolimus, and min-
imal-dose calcineurin inhibitor. Alemtuzumab was used
instead of daclizumab in the Edmonton Protocol. During a
mean follow-up time of 18.3 months (range 13–31), four
patients became insulin independent and three patients
reduced insulin dose to about 75% the amount required
before transplantation. The serum concentrations of C-
peptide were all above 0.5 nmol/l. All patients had near-
normal A1C values after transplantation. No acute and
chronic rejections were observed for the transplanted
kidney, as indicated by the normal kidney function. An-
other important ﬁnding is that none of the recipients had a
percentage of panel reactive antibodies above 5% over
follow-up. Also, none of the patients became antibody
positive for islet cells.
Although the number of patients limits deﬁnite conclu-
sions, this study demonstrates that a glucocorticoid-free
immunosuppressive protocol that includes alemtuzumab,
sirolimus, and minimal dose of calcineurin inhibitor is
effective and safe for simultaneous kidney and islet trans-
plantation. It provides clear beneﬁts for patients with type
1 diabetes and end-stage renal disease in terms of improv-
ing variations in blood glucose and alleviating problematic
hypoglycemia. The net harm versus beneﬁt of simulta-
neous kidney and islet transplantation has not yet been
established and will require further studies with larger
numbers of enrolled subjects. Also, our induction regimen
cannot be directly compared with the Edmonton Protocol
or other more standard induction (for example, thymo-
globulin or antiIL-2R therapy) because the dataset is small.
Studies to analyze the beneﬁt of the present induction
regimen in a longitudinal follow-up are necessary.
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